Septerna (SEPN) Revenue & Revenue Breakdown
Septerna Revenue Highlights
Latest Revenue (Y)
$1.07M
Latest Revenue (Q)
$21.50M
Septerna Revenue by Period
Septerna Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.07M | 611.92% |
| 2023-12-31 | $151.00K | 100.00% |
| 2022-12-31 | - | - |
Septerna generated $1.07M in revenue during NA 2024, up 611.92% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Septerna Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $21.50M | 17963.03% |
| 2025-06-30 | $119.00K | -45.66% |
| 2025-03-31 | $219.00K | 3.30% |
| 2024-12-31 | $212.00K | 20.45% |
| 2024-09-30 | $176.00K | -52.43% |
| 2024-06-30 | $370.00K | 16.72% |
| 2024-03-31 | $317.00K | 168.64% |
| 2023-12-31 | $118.00K | 257.58% |
| 2023-09-30 | $33.00K | - |
Septerna generated $21.50M in revenue during Q3 2025, up 17963.03% compared to the previous quarter, and up 5809.46% compared to the same period a year ago.
Septerna Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.70B | $701.30M |
| MRVI | Maravai LifeSciences | $259.19M | $41.63M |
| NRIX | Nurix Therapeutics | $54.55M | $7.89M |
| KURA | Kura Oncology | $53.88M | $20.75M |
| EYPT | EyePoint Pharmaceuticals | $43.27M | $966.00K |
| TNGX | Tango Therapeutics | $42.07M | $53.81M |
| ABUS | Arbutus Biopharma | $6.17M | $529.00K |
| PRME | Prime Medicine | $2.98M | $1.23M |
| SEPN | Septerna | $1.07M | $21.50M |
| PROK | ProKidney | $76.00K | $217.00K |
| BCAX | Bicara Therapeutics | - | - |